22:45 , Apr 12, 2019 |  BioCentury  |  Emerging Company Profile

Bright Angel: New hope against fungal resistance

Bright Angel is tackling antifungal resistance at its root with inhibitors of Hsp90 and other stress response factors, unlike competitors that are developing compounds against known or new pathways where resistance can still emerge. Resistance...
00:24 , Apr 12, 2019 |  BC Innovations  |  Product Development

NLRP3 early and often

Inflammasome inhibitors could offer a step change for a slew of inflammatory diseases and pharma is taking notice. Two acquisitions in six months show the first inflammasome target -- NLRP3 -- is gaining momentum, but...
01:49 , Mar 22, 2019 |  BC Innovations  |  Targets & Mechanisms

Deconvoluting translation at Scripps

With three institutes now under one roof, Scripps Research has established both its own pipeline and a non-profit funding model to bring candidates through early stage clinical trials. Diverging from the philanthropy and investor-based approaches...
14:29 , Mar 19, 2019 |  BC Innovations  |  Distillery Therapeutics

New brain-penetrating RIPK2 inhibitor prodrug for GBM

DISEASE CATEGORY: Cancer INDICATION: Brain cancer Cell culture and mouse studies identified a brain-penetrating naphthoquinone-based prodrug of a RIPK2 inhibitor that could help treat glioblastoma multiforme (GBM). Screening a library of drug-like small molecules in...
22:55 , Feb 22, 2019 |  BioCentury  |  Finance

MPM keeps building

MPM Capital’s new $400 million BioVentures 2018 fund will complement the firm’s cancer-focused initiatives and enable it to continue its company building strategy. BioVentures 2018 closed on Feb. 21 and follows in the footsteps of...
19:08 , Feb 22, 2019 |  BC Week In Review  |  Financial News

MPM closes $400M BioVentures 2018 fund

MPM Capital closed BioVentures 2018 at $400 million to fund early stage biotechs. BioVentures 2018, the firm's seventh fund, will invest in therapeutic areas including oncology, immunology and neuroscience, as well as in modalities such...
12:00 , Feb 21, 2019 |  BC Extra  |  Financial News

MPM closes $400M BioVentures 2018 fund

MPM Capital closed BioVentures 2018 at $400 million to fund early stage biotechs. BioVentures 2018, the firm's seventh fund, will invest in therapeutic areas including oncology, immunology and neuroscience, as well as in modalities such...
00:49 , Feb 16, 2019 |  BioCentury  |  Emerging Company Profile

NodThera: Inhibiting the inflammasome for NASH

NodThera Ltd. is tackling both the inflammation and fibrosis that drive NASH by inhibiting the NLRP3 inflammasome, a target few companies have interrogated for the indication. With a £28 million ($37 million) series A led...
20:27 , Oct 12, 2018 |  BioCentury  |  Finance

Spinning out Sitryx

With a $30 million series A round and a pipeline of immunometabolism programs, Sitryx Therapeutics Ltd. became the first start-up to emerge from the Immunology Network at GlaxoSmithKline plc (LSE:GSK; NYSE:GSK). The round, which closed...
18:13 , Oct 12, 2018 |  BC Week In Review  |  Financial News

Immunometabolism company Sitryx debuts with GSK ties, $30M

Sitryx Therapeutics Ltd. (Oxford, U.K.) emerged from stealth on Oct. 8 with $30 million from a series A round to develop disease-modifying therapeutics for immuno-oncology and immuno-inflammation, which CEO Neil Weir expects to be enough...